MilliporeSigma Webinars
-
Biosafety In Gene Therapy: Applying The Latest Regulatory Guidance For RCL Testing
2/23/2021
The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach. For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production.
-
The In Vitro Pyrogen Test For Pharmaceutical Batch Release
2/5/2021
The monocyte activation test (MAT) provides an in vitro alternative to conventional animal testing methods. Discover the benefits of a ready-to-use Monocyte Activation Test kit, and examine a real-life case study.
-
Assess Pyrogenic Risk With The Monocyte Activation Test
2/5/2021
Microbial risk in pharmaceutical processing cannot be limited to viable microorganisms. Learn how the MAT can help you to assess the pyrogenic risk resulting from your production process.
-
Unlocking The Potential Of mRNA Vaccines And Therapeutics: A Manufacturing Perspective
1/12/2021
This webinar highlights the potential of mRNA therapies and focuses on the manufacturing process associated challenges, solutions and perspectives from synthesis to delivery.
-
Re-Imagining Vaccine Manufacturing To Address Global Health Challenges
10/27/2020
In the last decade, biopharmaceutical industries have mobilized quickly in response to pandemics. Developing vaccines and manufacturing large doses in response to an emergency is often constrained by existing platforms and facility configurations. Learn how vaccine manufacturing can evolve to tackle future global health challenges.
-
Addressing The Challenge Of Scalability In Viral Vectors
10/18/2020
Early viral vector process development for cell and gene therapies is critical to assure a production strategy that supports commercial needs. In this webinar, you will learn the importance of planning for scalability and manufacturability from the earliest stages of process development and how a scalable templated process can reduce time needed to move from product development to commercialization.
-
Evaluating Viral Clearance For Continuous Processes
10/18/2020
Is viral clearance a hurdle to implementing continuous processing? Here we share virus spiking alternatives that may pave the way for evaluating viral clearance by chromatography steps.
-
Navigating The Road To Gene Therapy Commercialization
8/27/2020
With increases in development and investments in the gene therapy field, companies will increasingly be looking at manufacturing and commercialization of their therapies. Road to commercialization goes through a series of process validation phases. In this webinar, we take a closer look at the road to commercialization and focus on addressing primary questions.
-
Downstream Process Intensification For Virus Purification
8/21/2020
With the rise of gene therapy as a promising treatment modality, the industry is facing increasing pressure to decrease overall manufacturing costs, shorten product development timelines and increase production. This webinar focuses on intensified downstream process using high-productivity, single-use chromatography membrane adsorbers.
-
How To Ensure Biosafety Of Novel Viral Therapies
11/7/2019
While no viral contamination has been reported so far for novel viral therapies, it is important to learn from historical experience and leverage improved manufacturing and testing methods to increase their safety.